Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Duragesic “Black Box” Should Include Pediatric Death Warning – Cmte.

Executive Summary

Enhanced Duragesic "black box" warnings on pediatric deaths are recommended by FDA's Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee

You may also be interested in...



Duragesic Risk Management Plan Under “Discussion”; New Warnings Added

Johnson & Johnson/Alza and FDA are discussing the creation of a risk management program for Duragesic, the agency said in a Feb. 4 letter approving labeling changes for the fentanyl transdermal system

Duragesic Risk Management Plan Under “Discussion”; New Warnings Added

Johnson & Johnson/Alza and FDA are discussing the creation of a risk management program for Duragesic, the agency said in a Feb. 4 letter approving labeling changes for the fentanyl transdermal system

SSRIs And Suicide To Be Discussed By Pediatric Advisory Cmte. In September

FDA's Pediatric Advisory Committee will hold its first meeting in September as a joint session with the Psychopharmacologic Advisory Committee

Related Content

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel